BioPharmSignal logoBioPharmSignal

Biotech News

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Day One Biopharmaceuticals (DAWN)Day One BiopharmaceuticalsCompany update

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of approximately $2.5 billion SURESNES, France and BRISBANE, Calif., March 06, 2026

Related news

TEVATeva Pharmaceutical Industries2026-06-10 16:03 EST

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

KURAKura Oncology2026-06-02 12:32 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-07-14 12:00 EST

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

KURAKura Oncology2026-06-03 10:53 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

View all latest news

Day One Biopharmaceuticals

Pediatric and Rare Oncology Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types. OJEMDA OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an...

Recent company news

DAWNDay One Biopharmaceuticals2026-03-06 13:30 EST

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

DAWNDay One Biopharmaceuticals2026-02-24 21:00 EST

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

DAWNDay One Biopharmaceuticals2026-02-10 13:30 EST

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

DAWNDay One Biopharmaceuticals2026-01-11 22:00 EST

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

DAWNDay One Biopharmaceuticals2026-01-06 14:02 EST

Day One Completes Acquisition of Mersana Therapeutics

Stock data

Close
21.53 USD
Market cap
2.22B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States